Salts of...

Details Salts of... Salts of...

2011-01-11

2011-01-11

Andres, Janet L (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S317000

Reexamination Certificate

active

07868176

ABSTRACT:
Disclosed herein are salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide including the citrate, fumarate, maleate, malate, phosphate, succinate, sulphate, and edisylate salts.

REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6214846 (2001-04-01), Elliott
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0192268 (2005-09-01), Ek et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2005/0261340 (2005-11-01), Weiner et al.
patent: 2005/0288328 (2005-12-01), Weiner et al.
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194784 (2006-08-01), Ek et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 2007/0260064 (2007-11-01), Tolf et al.
patent: 984843 (1978-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062208 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/009549 (2004-01-01), None
patent: WO 2004/039322 (2004-05-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO 2004/084738 (2004-08-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
Berge et al J. Pharm. Sci. 1977, 66, 1-19.
T.W. Graham Solomons and Craig B. Fryhle “Organic Chemistry” 9thEdition, John Wiley & Sons, Inc. 2008, pp. 903-909.
Cox, R., “Medicinal Chemistry- 28thInternational Symposium: Jun. 8-12, 2002, San Diego, CA, USA,”IDrugs, vol. 5, No. 7, pp. 626-632 (2002).
Johnston et al., “Drugs in Development for Parkinson's Disease: An Update,”Current Opin. Investig. Drugs, vol. 7, No. 1, pp. 25-32 (2006).
Maubach, K., “Psychiatric Drug Discovery and Development,”Expert Opin. Investig. Drugs., vol. 12, No. 9, pp. 1571-1575 (2003).
Meltzer et al., “Serotonin Receptors: Their Key Role in Drugs to Treat Schizophrenia,”Progress in Neuro-Pyschopharmacology&Biol. Psych., vol. 27, pp. 1159-1172 (2003).
Morgan et al., “Emerging Drugs for Parkinson's Disease,”Expert Opin. Emerging Drugs., vol. 11, No. 3, pp. 403-417(2006).
Roberts, C. “Drug Evaluation: ACP-103, a 5-HT2A Receptor Inverse Agonist,”Current Opin. Investig. Drugs, vol. 7, No. 7, pp. 653-660 (2006).
Vanover et al., “ACP-103, A 5-HT2A Receptor Inverse Agonist, A Novel Potential Treatment For Psychosis,”Schizophrenia Research, vol. 60, No. 1, Supp. [S], p. 317 (2003).
Vanover et al., “ACP-103, A 5-HT2A Receptor Inverse Agonist: Safety, Tolerability and Pharmacokinetics in Healthy Volunteers,”International J. Neuropsychopharmacology, vol. 7, No. Supp. 2, pp. S253 (2004).
Vanover et al., “Pharmacological and Behavioral Profile ofN-(4-fluorophenylmethyl)-N-(1-methylpiperidin'4- yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R, 3R)-Dihydroxybutanedioate (2:!) (ACP-103), a Novel 5-Hydroxytrptamine 2A Receptor Inverse Agonist,”J. Pharmacology&Experimental Therapeutics, vol. 317, No. 2, pp. 910-918 (2006).
R & D Focus Drug News, vol. 10, No. 44, pp. 1-6 (Nov. 12, 2001).
Office Action dated Jan. 6, 2009 in U.S. Appl. No. 10/759,561.
Declaration of Dr. Douglas W. Bonhaus, filed Oct. 14, 2008 in U.S. Appl. No. 10/759,561.
Office Action dated Jul. 11, 2008 in U.S. Appl. No. 10/759,561.
Office Action dated Oct. 10, 2007 in U.S. Appl. No. 10/759,561.
Office Action dated Jan. 15, 2009 in U.S. Appl. No. 11/235,558.
Office Action dated Jan. 22, 2009 in U.S. Appl. No. 11/417,447.
Acadia Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis,Press Release(Business Wire, San Diego), Sep. 1, 2009.
Acadia Pharmaceuticals Provide Update on Pimavanserin Collaborative Development Program,Press Release(Business Wire, San Diego), Oct. 6, 2009.
Jones et al., “Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement,”Mater. Res. Bull.,31:875-79 (2006).
Andrew D. Bond & William Jones, Controlling Crystal Architecture in Molecular Solids: The Supramolecular Approach, in Supramolecular Organization and Materials Design, 391, 436 (W. Jones & C. N. R. Rao, eds., 2001).
Notice of Allowance dated Jun. 17, 2009 in U.S. Appl. No. 10/759,561.
Caroon, et al. 1981. Synthesis and anatypertensive activity of a series of 8-substituted 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones.J. Med. Chem., 24:1320-1328.
Chemical Abstracts, 73:25305. Benke, et al. 1970.
Clifton, et al. 1982. Arylethanolamines Derived from Salicyclamide with α- and 

Affiliated with

Also associated with

Rating

Salts of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Salts of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salts of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2705318